Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulationThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease.
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Defective iron utilization leading to either systemic or regional misdistribution of the metal has been identified as a critical feature of several different disorders. Iron concentrations can rise to toxic levels in mitochondria of excitable cells, often leaving the cytosol iron-depleted, in some forms of neurodegeneration with brain accumulation (NBIA) or following mutations in genes associated with mitochondrial functions, such as ABCB7 in X-linked sideroblastic anemia with ataxia (XLSA/A) or the genes encoding frataxin in Friedreich’s ataxia (FRDA). In anemia of chronic disease (ACD), iron is withheld by macrophages, while iron levels in extracellular fluids (e.g., plasma) are drastically reduced. One possible therapeutic approach to these diseases is iron chelation, which is known to effectively reduce multiorgan iron deposition in iron-overloaded patients. However, iron chelation is probably inappropriate for disorders associated with misdistribution of iron within selected tissues or cells. One chelator in clinical use for treating iron overload, deferiprone (DFP), has been identified as a reversed siderophore, that is, an agent with iron-relocating abilities in settings of regional iron accumulation. DFP was applied to a cell model of FRDA, a paradigm of a disorder etiologically associated with cellular iron misdistribution. The treatment reduced the mitochondrial levels of labile iron pools (LIP) that were increased by frataxin deficiency. DFP also conferred upon cells protection against oxidative damage and concomitantly mediated the restoration of various metabolic parameters, including aconitase activity. Administration of DFP to FRDA patients for 6 months resulted in selective and significant reduction in foci of brain iron accumulation (assessed by T2* MRI) and initial functional improvements, with only minor changes in net body iron stores. The prospects of drug-mediated iron relocation versus those of chelation are discussed in relation to other disorders involving iron misdistribution, such as ACD and XLSA/A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800 · cited 2×
“It is unclear whether ACD is an undesirable side effect of pathologic stress brought on by inflammation or a defence mechanism for withholding iron from invading pathogens (Weiss and Goodnough 2005; Weiss 2009).”
BackgroundImaging iron stores in the brain using magnetic resonance imaging
Haacke, E. M., Cheng, N. Y. C., House, M. J., Liu, Q., Neelavalli, J., Ogg, R. J., Khan, A., Ayaz, M., Kirsch, W., & Obenaus, A. (2005) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2004.10.001 · Cited by 995
Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia
Rötig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., Munnich, A., & Rustin, P. (1997) · Nature Genetics · doi:10.1038/ng1097-215 · Cited by 991
Kakhlon, O., & Cabantchik, Z. I. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01006-7 · Cited by 839 · cited 3×
“, redox-active and chelatable) (Kakhlon and Cabantchik 2002).”
BackgroundSelf-citationPuccio, H., Simon, D., Cossée, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P., & Koenig, M. (2001) · Nature Genetics · doi:10.1038/84818 · Cited by 738
Metals in Alzheimer's and Parkinson's Diseases
Barnham, K. J., & Bush, A. I. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.019 · Cited by 695
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)
Finberg, K. E., Heeney, M. M., Campagna, D. R., Aydınok, Y., Pearson, H. A., Hartman, K. R., Mayo, M. M., Samuel, S. M., Strouse, J. J., Markianos, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.130 · Cited by 675
A cytosolic iron chaperone that delivers iron to ferritin
Shi, H., Bencze, K. Z., Stemmler, T. L., & Philpott, C. C. (2008) · Science · doi:10.1126/science.1157643 · Cited by 536
Selective iron chelation in Friedreich ataxia: biologic and clinical implications
Boddaert, N., Le Quan Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.-C., Munnich, A., & Cabantchik, Z. I. (2007) · Blood · doi:10.1182/blood-2006-12-065433 · Cited by 409
Self-citationWong, A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.425 · Cited by 374 · cited 1×
“High-affinity iron chelators have been found to alleviate oxidative stress of both endogenous and exogenous origin in FRDA models (Wong et al. 1999; Richardson 2004; Li et al. 2008; Lim et al. 2008; Whitnall et al. 2008).”
Background
Research works printed but not linked: 65
- 10.1021/jm070800l · DOI · Paper page
- Bottomley S.S., 2006, Curr. Hematol. Rep., 5, 41
- 10.1182/blood.V97.3.792 · DOI · Paper page
- 10.1016/j.nurt.2008.05.001 · DOI · Paper page
- 10.1111/j.1365-2141.2008.07290.x · DOI
- 10.1182/blood-2002-10-3280 · DOI · Paper page
- 10.1016/S1474-4422(07)70220-X · DOI · Paper page
- 10.1111/j.1600-0609.2007.00840.x · DOI
- 10.1006/abio.1997.2126 · DOI · Paper page
- Evans R.W., 1992, Drugs Today (Barc), 28, 19
- 10.1002/mds.22002 · DOI · Paper page
- 10.1016/0300-483X(95)03301-U · DOI
- 10.1002/pbc.20656 · DOI · Paper page
- 10.1182/blood-2005-02-0460 · DOI · Paper page
- 10.1182/blood-2006-05-020867 · DOI · Paper page
- Gregory A., 2005, Folia Neuropathol., 43, 286
- Gutteridge J.M.C., 2000, Ann. N. Y. Acad. Sci., 899, 136, 10.1111/j.1749-6632.2000.tb06182.x · DOI · Paper page
- 10.1016/S0006-2952(99)00031-3 · DOI
- 10.1172/JCI115422 · DOI · Paper page
- 10.1016/j.spen.2006.08.007 · DOI
- 10.1111/j.1365-2141.2004.04946.x · DOI · Paper page
- 10.1196/annals.1345.015 · DOI
- 10.1021/bi990438f · DOI · Paper page
- 10.1046/j.1365-2141.1996.d01-1795.x · DOI · Paper page
- 10.1196/annals.1306.023 · DOI · Paper page
- 10.1182/blood-2008-06-161919 · DOI · Paper page
- Konijn A.M., 1999, Blood, 94, 2128, 10.1182/blood.V94.6.2128 · DOI · Paper page
- 10.1039/an9952000845 · DOI
- 10.1016/S0140-6736(87)90545-9 · DOI · Paper page
- 10.1093/hmg/ddn127 · DOI · Paper page
- 10.1146/annurev.biochem.76.052705.162653 · DOI · Paper page
- 10.1124/mol.108.046847 · DOI
- 10.1111/j.1440-1681.2008.05114.x · DOI
- 10.1136/gut.2003.030429 · DOI · Paper page
- 10.1016/0140-6736(91)92978-B · DOI · Paper page
- 10.1177/1352458507078916 · DOI · Paper page
- 10.1016/j.ajhg.2007.12.012 · DOI · Paper page
- 10.1007/s10534-006-9033-z · DOI · Paper page
- 10.1182/blood-2004-10-3856 · DOI · Paper page
- 10.1007/s00415-009-1002-3 · DOI · Paper page
- 10.1007/s00415-009-1003-2 · DOI · Paper page
- 10.1515/BC.2002.051 · DOI · Paper page
- 10.1002/ajh.21100 · DOI · Paper page
- 10.1007/s00415-009-1004-1 · DOI
- 10.1196/annals.1306.026 · DOI · Paper page
- Richardson D.R., 2001, Biochim. Biophys. Acta, 1536, 133, 10.1016/S0925-4439(01)00041-2 · DOI · Paper page
- 10.1016/j.tig.2008.05.008 · DOI · Paper page
- 10.1159/000065700 · DOI · Paper page
- 10.1073/pnas.88.15.6585 · DOI · Paper page
- Singh S., 1995, Biochem. Soc. Symp., 61, 127, 10.1042/bss0610127 · DOI · Paper page
- 10.1136/jnnp.2007.120568 · DOI
- Spivak J.L., 2002, Oncology (Williston Park), 16, 25
- 10.1016/S0140-6736(89)92011-4 · DOI
- 10.1136/ard.49.11.956-b · DOI
- Vreugdenhil G., 1991, Clin. Exp. Rheumatol., 9, 35
- 10.1016/0006-2952(93)90222-I · DOI
- 10.1002/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H · doi:10.1002/1531-8249(199907)46:1<123::aid-ana19>3.0.co;2-h
- 10.1016/0006-2952(94)00521-M · DOI
- 10.1016/j.bbagen.2008.08.006 · DOI · Paper page
- 10.1073/pnas.0804261105 · DOI · Paper page
- 10.1016/j.spen.2006.08.005 · DOI
- 10.1007/BF03033574 · DOI
- Zanella I., 2008, Biochim. Biophys. Acta, 1782, 90, 10.1016/j.bbadis.2007.11.006 · DOI
- Zanninelli G., 1997, Mol. Pharmacol., 51, 842, 10.1124/mol.51.5.842 · DOI
- 10.1038/ng572 · DOI · Paper page
Cited by
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5593 · Cited by 619
Self-citationKell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“As would be expected, appropriate iron chelation may have therapeutic benefits (Boddaert et al. 2007; Campanella et al. 2009; Goncalves et al. 2008; Kakhlon et al. 2010; Lim et al. 2008; Marmolino and Acquaviva 2009; Santos et al. 2010; Schulz et al. 2009; Sohn et al. 2008).”
BackgroundLabile iron in cells and body fluids: Physiology, pathology, and pharmacology
Cabantchik, Z. I. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00045 · Cited by 306
“…cells and extracellular Tf, it has also the ability to correct iron maldistribution per se (Sohn et al., 2008, 2011; Breuer and Cabantchik, 2009; Kakhlon et al., 2010; e.g., between mitochondria and cytosol, as found in cells rendered frataxin deficient by shRNA suppression technology) as well…”
BackgroundSelf-citationIron, oxidative stress and the example of solar ultraviolet a radiation.
Aroun, A., Zhong, J. L., Tyrrell, R. M., & Pourzand, C. (2012) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05204g · Cited by 74
Iron chelation and multiple sclerosis
Weigel, K. J., Lynch, S. G., & LeVine, S. M. (2014) · ASN NEURO · doi:10.1042/an20130037 · Cited by 63
“An iron chelator binds iron and promotes its removal, and in some cases a chelator has been shown to alter the distribution of iron within cells (Kakhlon et al., 2008, 2010; Sohn et al., 2008; Szuber et al., 2008).”
Background
Metadata
- Authors
- Kakhlon, O., Breuer, W., Munnich, A., & Cabantchik, Z. I.
- Venue
- Canadian Journal of Physiology and Pharmacology
- Publisher
- Canadian Science Publishing
- Published
- 2010-03
- Volume
- 88
- Issue
- 3
- Pages
- 187-196
- ISSN
- 0008-4212 (ISSN-L)
- 1205-7541
- OpenAlex
- W1513950293
- Cited by
- 48
- References
- 25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.nrcresearchpress.com/page/about/CorporateTextAndDataMining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulationThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease. https://app.cochat.ai/papers/10.1139/y09-128
- The paper
- Kakhlon, O., Breuer, W., Munnich, A., & Cabantchik, Z. I. (2010). Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulationThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/y09-128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.